Trials / Terminated
TerminatedNCT05075304
A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients
A Phase Ib, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BDB-001 Injection in Patients With Novel Coronavirus (2019-nCoV) Infection
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This open, multi-center, multiple ascending dose study was designed to evaluate the safety, tolerability, preliminary efficacy and PK/PD of BDB-001 injection in patients with mild, or general COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BDB-001 injection | IV infusions of Injection diluted in sodium chloride |
| DRUG | BDB-001 injection | IV infusions of Injection diluted in sodium chloride |
| DRUG | BDB-001 injection | IV infusions of Injection diluted in sodium chloride |
Timeline
- Start date
- 2020-02-21
- Primary completion
- 2020-04-14
- Completion
- 2020-04-14
- First posted
- 2021-10-12
- Last updated
- 2024-05-21
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05075304. Inclusion in this directory is not an endorsement.